AI assistant
LISATA THERAPEUTICS, INC. — Director's Dealing 2021
Dec 10, 2021
34931_dirs_2021-12-10_d63ef42d-6d86-4a97-a996-901f8601b507.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CALADRIUS BIOSCIENCES, INC. (CLBS)
CIK: 0000320017
Period of Report: 2021-12-08
Reporting Person: MYERS STEVEN S (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-12-08 | Common Stock | P | 33785 | $0.8936 | Acquired | 146839 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 8434 | Indirect |
| Common Stock | 1954 | Indirect |
| Common Stock | 802 | Indirect |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8802 to $0.9000, inclusive. The reporting person undertakes to provide Caladrius Biosciences, Inc., any security holder of Caladrius Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F2: Represents 37,735 unvested restricted stock awards granted under Issuer's 2018 Equity Incentive Compensation plan, which will vest on January 11, 2022.